Drugs · acquisition-cost intelligence
Keppra XR
levetiracetam· ingredient levetiracetamOther antiepileptics· LEVETIRACETAM 1000 mg/1; LEVETIRACETAM 500 mg/1; LEVETIRACETAM 750 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.24408
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other levetiracetam products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Levetiracetam | $0.03031 | −$0.21380 |
| Roweepra | $0.07804 | −$0.16600 |
| levetiracetam | $0.09735 | −$0.14670 |
| Spritam | $10.27 | +$10.03 |
Medicare Part D coverage · CY2026
On 313 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 18% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.